Country (Ref) | Year | Patients (n) | Poly% | Prevalence* | VPA % | CBZ % | PHT % | PBT % | LTG % | TPM % | LEV % | OXC % | Others (%) |
Croatia39 | 2005 | 258 | 22 | – | 51 | 17 | – | 17 | 13 | 28 | – | – | – |
Germany40 | 2004–2006 | 13 197 | 25 | 41 | 32 | 7 | – | 5 | 15 | 6 | 4 | 10 | STM (11), ETX (1), VGB (1) |
Germany31 | 2009 | 2361 | 42 | 52 | 24 | 11 | – | – | 9 | – | 7 | 7 | – |
Italy17‡ | 2003–2010 | 10 255 | 28§ | 64 | 14 | 0.2 | 8 | 1 | 2 | 2 | 3 | ETX (1), CZP (0.5), GBP (0.3) | |
Italy28 | 2001–2005 | 375 | – | 39 | – | – | – | – | 6 | 11 | 4 | 5 | VGB (4), felbamate (0.3) |
The Netherlands7 | 1997–2005 | 1527 | 20 | 22 | 66 | 23 | 2 | 5 | 16 | – | 4 | 3 | – |
The Netherlands28 | 2001–2005 | – | – | – | – | – | – | 11 | 2 | 3 | 8 | VGB (3), GBP (8), pregabalin (2) | |
Norway13 | 2004–2009 | 4015 | 18 | 91† | 42 | 19 | 2 | 0 | 34 | 10 | 12 | 8 | CZP (7), GBP (2) |
UK9 | 1993–2008 | – | 27 | – | 56/50 | – | 4/1 | 3/2 | 4/22 | – | 0/10 | – | – |
UK28 | 2001–2005 | 578 | – | 30 | – | – | – | – | 14 | 7 | 4 | 2 | VGB (2), GBP (1) TGB (0.3) |
Wales12 | 2000–2010 | 992 | – | – | 76/61 | 14/10 | – | – | 11/21 | – | 0/8 | – | – |
Data for empty cells not available. Data before and after slash represent the earliest and most recent data for the study, respectively.
*AED prevalence per 10 000 persons.
†Prevalence for last year of study.
‡Incident monotherapy users.
§Prevalence per 10 000 person-years.
CBZ, carbamazepine; CZP, clonazepam; ETX, ethosuximide; GBP, gabapentin; LEV, levetiracetam; LTG, lamotrigine; OXC, oxcarbazepine; PBT, phenobarbital; PHT, phenytoin; poly, polytherapy; STM, sulthiame; TGB, tiagabine; TPM, topiramate; VGB, vigabatrin; VPA, sodium valproate.